Skip to main content

Advertisement

Log in

Pseudolaric acid B inhibits inducible cyclooxygenase-2 expression via downregulation of the NF-κB pathway in HT-29 cells

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Pseudolaric acid B (PAB) is a diterpene acid isolated from the root and trunk bark of Pseudolaric kaempferi Gordon. Previous work has found that PAB has anti-inflammatory and anti-tumor effects in xenograft models of human hepatocellular carcinoma. The aim of this study is to evaluate the correlation between anti-cancer and anti-inflammatory effects of PAB and its molecular mechanisms on HT-29 cells.

Methods

Production of prostaglandin E2 (PGE2) in HT-29 cells was evaluated by ELISA. mRNA of cyclooxygenase-2 (COX-2) was analyzed by RT-PCR assay. High-content screening (HCS) method was adopted to detect the cytokine mixture (CM)-induced transcription activity of NF-κB and STAT3. Western blotting was used to evaluate the protein expression levels of inflammatory mediators induced by CM. After treatment with PAB in various concentrations, the inhibition rate of cell proliferation was measured with sulforhodamine B assays. For the in vivo studies, tumor-bearing models xenografted with HT-29 cells were developed in nude mice, and following oral administration with PAB, tumor inhibition rate was calculated.

Results

PAB inhibited the PGE2 production in HT-29 cells significantly (P < 0.05) with similar results detected at the COX-2 mRNA level. Furthermore, PAB suppressed the COX-2 protein expression and significant nuclear translocation of NF-κB and STAT3 induced by CM, which correlated with a concomitant degradation of I-κB and a decrease in constitutive STAT3 phosphorylation (P < 0.05). Moreover, various concentrations of PAB inhibited the proliferation of HT-29 cells in a dose- and time-dependent manner. In vivo, after treatment with PAB for 17 days, the tumor weight of the 50 and 100 mg/kg treated groups was 0.62 ± 0.15 and 0.54 ± 0.06 g, respectively. When compared to the control group (0.82 ± 0.16 g), the inhibition rate of tumor weight was 24.2% at 50 mg/kg (P < 0.05) and 34.7% at 100 mg/kg (P < 0.001).

Conclusions

PAB shows potential anti-cancer activity in HT-29 cells, and its molecular mechanisms are related to the anti-inflammatory action.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  • Alexander WS (2002) Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2:410–416

    PubMed  CAS  Google Scholar 

  • Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J et al (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885–895

    Article  PubMed  CAS  Google Scholar 

  • Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C (1999) Stat3 as an oncogene. Cell 98:295–303

    Article  PubMed  CAS  Google Scholar 

  • Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H et al (2007) The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 26:2822–2832

    Article  PubMed  CAS  Google Scholar 

  • Chen WG, Daines MO, Khurana Hershey GK (2004) Turning off signal transducer and activator of transcription (STAT): The negative regulation of STAT signaling. J Allergy Clin Immunol 114:476–489

    Article  PubMed  CAS  Google Scholar 

  • Dixon DA (2004) Dysregulated post-transcriptional control of COX-2 gene expression in cancer. Curr Pharm Des 10:635–646

    Article  PubMed  CAS  Google Scholar 

  • Gong XF, Wang MW, Tashiro S, Onodera S, Ikejima T (2006) Involvement of JNK-initiated p53 accumulation and phosphorylation of p53 in pseudolaric acid B induced cell death. Exp Mol Med 38:428–434

    PubMed  CAS  Google Scholar 

  • Grivennikov S, Karin M (2008) Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 13:7–9

    Article  PubMed  CAS  Google Scholar 

  • Grivennikov SI, Karin M (2010) Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21:11–19

    Article  PubMed  CAS  Google Scholar 

  • Hou GQ, Zhang Q, Wang LL, Liu MY, Wang JR, Xue LX (2010) mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice. Cancer Lett 290:248–254

    Article  PubMed  CAS  Google Scholar 

  • Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW (2003) Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 284:31–53

    Article  PubMed  CAS  Google Scholar 

  • Kim HS, Cho IH, Kim JE, Shin YJ, Jeon JH, Kim Y et al (2008) Ethyl pyruvate has an anti-inflammatory effect by inhibiting ROS-dependent STAT signaling in activated microglia. Free Radical Bio Med 45:950–963

    Article  CAS  Google Scholar 

  • Ko JKS, Leung WC, Ho WK, Chiu P (2007) Herbal diterpenoids induce growth arrest and apoptosis in colon cancer cells with increased expression of the nonsteroidal anti-inflammatory drug-activated gene. Eur J Pharmacol 559:1–13

    Article  PubMed  CAS  Google Scholar 

  • Kojima M, Morisaki T, Izuhara K, Uchiyama A, Matsunari Y, Katano M et al (2000) Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-kB activation. Oncogene 19:1225–1231

    Article  PubMed  CAS  Google Scholar 

  • Kraus S, Arber N (2009) Inflammation and colorectal cancer. Curr Opin Pharmacol 9:405–410

    Article  PubMed  CAS  Google Scholar 

  • Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z et al (2009) Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15:283–293

    Article  PubMed  CAS  Google Scholar 

  • Li T, Wong VKW, Yi XQ, Wong YF, Zhou H, Liu L (2009) Pseudolaric acid B suppresses T lymphocyte activation through inhibition of NF-kappaB signaling pathway and p38 phosphorylation. J Cell Biochem 108:87–95

    Article  PubMed  CAS  Google Scholar 

  • Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia WY, Wei YK et al (2005) Nuclear interaction of p-EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7:575–589

    Article  PubMed  CAS  Google Scholar 

  • Macarthur M, Hold GL, El-Omar EM (2004) Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 286:G515–G520

    Article  PubMed  CAS  Google Scholar 

  • Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grösch S (2004) Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67:1469–1478

    Article  PubMed  CAS  Google Scholar 

  • Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444

    Article  PubMed  CAS  Google Scholar 

  • Meng AG, Jiang LL (2009) Induction of G2/M arrest by pseudolaric acid B is mediated by activation of the ATM signaling pathway. Acta Pharmacol Sin 30:442–450

    Article  PubMed  CAS  Google Scholar 

  • Naugler WE, Karin M (2008) The wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14:109–119

    Article  PubMed  CAS  Google Scholar 

  • Ogunwobi OO, Beales ILP (2006) Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase-independent pathways. Regul Pept 134:1–8

    Article  PubMed  CAS  Google Scholar 

  • Pan DJ, Li ZL, Hu CQ, Chen K, Chang JJ, Lee KH (1990) The cytotoxic principles of Pseudolarix kaempferi: pseudolaric acid-A and-B and related derivatives. Planta Med 56:383–385

    Article  PubMed  CAS  Google Scholar 

  • Roessner A, Kuester D, Malfertheiner P, Schneider-Stock R (2008) Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol Res Pract 204:511–524

    Article  PubMed  CAS  Google Scholar 

  • Seruga B, Zhang H, Bernstein LJ, Tannock IF (2008) Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 8:887–899

    Article  PubMed  CAS  Google Scholar 

  • Shiff SJ, Shivaprasad P, Santini DL (2003) Cyclooxygenase inhibitors: drugs for cancer prevention. Curr Opin Pharmacol 3:352–361

    Article  PubMed  CAS  Google Scholar 

  • Simpson PB, Wafford KA (2006) New directions in kinetic high information content assays. Drug Discov Today 11:237–244

    Article  PubMed  CAS  Google Scholar 

  • Tak PP, Firestein GS (2001) NF-κB: a key role in inflammatory diseases. J Clin Invest 107:7–11

    Article  PubMed  CAS  Google Scholar 

  • Tan WF, Li MH, Chen Y, Ding J (2004) Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect. Eur J Pharmacol 499:219–228

    Article  PubMed  CAS  Google Scholar 

  • Terzic′ J, Grivennikov S, Karin E, Karin M (2010) Inflammation and colon cancer. Gastroenterology 138:2101–2114

    Article  Google Scholar 

  • Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anti-cancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252–266

    Article  PubMed  CAS  Google Scholar 

  • Tong YG, Zhang XW, Geng MY, Yue JM, Xin XL, Tian F et al (2006) Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin. Mol Pharmacol 69:1226–1233

    Article  PubMed  CAS  Google Scholar 

  • Wang D, DuBois RN (2008) Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett 267:197–203

    Article  PubMed  CAS  Google Scholar 

  • Wong VK, Chiu P, Chung SS, Chow LM, Zhao YZ, Yang BB et al (2005) Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits anti-tumor activity in vivo. Clin Cancer Res 11:6002–6011

    Article  PubMed  CAS  Google Scholar 

  • Wu T (2006) Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev 32:28–44

    Article  PubMed  CAS  Google Scholar 

  • Yu ZY, Zhang WZ, Kone BC (2002) Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem J 367:97–105

    Article  PubMed  CAS  Google Scholar 

  • Yu H, Kortylewski M, Pardoll D (2007a) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Rev Immunol 7:41–51

    Article  CAS  Google Scholar 

  • Yu JH, Cui Q, Jiang YY, Yang W, Tashiro SI, Onodera S et al (2007b) Pseudolaric acid B induces apoptosis, senescence, and mitotic arrest in human breast cancer MCF-7. Acta Pharmacol Sin 28:1975–1983

    Article  PubMed  CAS  Google Scholar 

  • Yu JH, Wang HJ, Li XR, Tashiro SI, Onodera S, Ikejima T (2008) Protein tyrosine kinase, JNK, and ERK involvement in pseudolaric acid B induced apoptosis of human breast cancer MCF-7 cells. Acta Pharmacol Sin 29:1069–1076

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by the Eleventh Five-Year Plan for National Science and Technology Major Project (Grant No. 2009ZX09301-010). We thank Dr. Jun-Qi Zheng (Tongji University School of Medicine) and Dr. Gautam Sethi (National University of Singapore) for their invaluable suggestions.

Conflict of interest

The authors declare no conflict of interest for this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jing-Rong Cui.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hou, L., Xu, B., Guo, W. et al. Pseudolaric acid B inhibits inducible cyclooxygenase-2 expression via downregulation of the NF-κB pathway in HT-29 cells. J Cancer Res Clin Oncol 138, 885–896 (2012). https://doi.org/10.1007/s00432-011-1120-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-011-1120-z

Keywords

Navigation